What are the AUA treatment guidelines for symptomatic, metastatic castration-resistant prostate cancer (CRPC) with poor performance status and no prior docetaxel chemotherapy?

Updated: Jul 31, 2017
  • Author: Bagi RP Jana, MD; more...
  • Print
Answer

Answer

Recommendations are as follows:

  • Abiraterone plus prednisone or enzalutamide

  • Ketoconazole plus steroid or radionuclide therapy to patients who are unable or unwilling to receive abiraterone plus prednisone

  • Docetaxel or mitoxantrone chemotherapy in select cases, specifically when performance status is directly related to the cancer

  • Radium-223 to patients with symptoms from bony metastases and without known visceral disease in select cases, specifically when the performance status is directly related to symptoms related to bone metastases.

  • Treatment with sipuleucel-T should not be offered


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!